Abstract
Introduction: Despite recent attention, there are no gender specific guidelines to address the disparity in bladder cancer survival between the sexes. The focus of this review was to identify areas of clinical practice that may influence bladder cancer outcomes and to provide evidence-based recommendations to improve bladder cancer survival in women. Method: A systematic search of MEDLINE was conducted to identify studies related to referral, diagnosis, treatment and outcomes of patients with bladder cancer with particular reference to gender differences. Results: Patients' knowledge of key signs and symptoms of bladder cancer is poor. There is evidence that there is a gender difference in referral patterns both at patient and primary care level. The presence of cystits, in particular, delays referral. Treatment and surveillance of high-risk non-muscle invasive cancers is variable and non-urothelial bladder cancer, which has higher incidence in women is more likely to be treated non-operatively than urothelial bladder cancer. Conclusion: We have offered recommendations to improve patient education and streamline referrals and suggested considerations for treatment of high-risk cancers to help improve survival in female bladder cancer patients.
References
1.
Micheli A, Mariotto A, Giorgi Rossi A, Gatta G, Muti P: The prognostic role of gender in survival of adult cancer patients. EUROCARE working group. Eur J Cancer 1998;34:2271-2278.
2.
Madeb R, Messing EM: Gender, racial and age differences in bladder cancer incidence and mortality. Urol Oncol 2004;22:86-92.
3.
Public Health England: Be Clear on Cancer. https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/08/bcoc-tri-partitie-letter-blood-in-pee-130815.pdf (accessed November 2, 2015).
4.
Cooper CP, Polonec L, Stewart SL, Gelb CA: Gynaecologic cancer symptom awareness, concern and care seeking among US women: a multi-site qualitative study. Fam Pract 2013;30:96-104.
5.
Henning A, Wehrberger M, Madersbacher S, et al: Do differences in clinical symptoms and referral patterns contribute to the gender gap in bladder cancer? BJU Int 2013;112:68-73.
6.
Aziz A, Madersbacher S, Otto W, et al: Comparative analysis of gender-related differences in symptoms and referral patterns prior to Initial diagnosis of urothelial carcinoma of the bladder: a prospective cohort study. Urol Int 2015;94:37-44.
7.
Hollenbeck BK, Dunn RL, Ye Z, et al: Delays in diagnosis and bladder cancer mortality. Cancer 2010;116:5235-5242.
8.
Mitra AP, Skinner EC, Schuckman AK, Quinn DI, Dorff TB, Daneshmand S: Effect of gender on outcomes following radical cystectomy for urothelial carcinoma of the bladder: a critical analysis of 1,994 patients. Urol Oncol 2014;32:52.e1-e9.
9.
Mommsen S, Aagaard J, Sell A: Presenting symptoms, treatment delay and survival in bladder cancer. Scand J Urol Nephrol 1983;17:163-167.
10.
Johnson EK, Daignault S, Zhang Y, Lee CT: Patterns of hematuria referral to urologists: does a gender disparity exist? Urology 2008;72:498-502; discussion 502-503.
11.
Cohn JA, Vekhter B, Lyttle C, Steinberg GD, Large MC: Sex disparities in diagnosis of bladder cancer after initial presentation with hematuria: a nationwide claims-based investigation. Cancer 2014;120:555-561.
12.
Lyratzopoulos G, Abel GA, McPhail S, Neal RD, Rubin GP: Gender inequalities in the promptness of diagnosis of bladder and renal cancer after symptomatic presentation: evidence from secondary analysis of an English primary care audit survey. BMJ Open 2013;pii:e002861.
13.
Santos F, Dragomir A, Kassouf W, Franco E, Aprikian A: Urologist referral delay and its impact on survival after radical cystectomy for bladder cancer. Curr Oncol 2015;22:20-26.
14.
NICE Guidelines [CG97] Lower Urinary Tract Symptoms in Men: Assessment and Management, 2010.
15.
Howles S, Tempest H, Doolub G, et al: Flexible cystoscopy findings in patients investigated for profound lower urinary tract symptoms, recurrent urinary tract infection, and pain. J Endourol 2012;26:1468-1472.
16.
Fowler JE Jr, Pulaski ET: Excretory urography, cystography, and cystoscopy in the evaluation of women with urinary-tract infection: a prospective study. N Engl J Med 1981;304:462-465.
17.
Tracey E, Watt H, Currow D, Young J, Armstrong B: Investigation of poorer bladder cancer survival in women in NSW, Australia: a data linkage study. BJU Int 2014;113:437-448.
18.
Abel GA, Shelton J, Johnson S, Elliss-Brookes L, Lyratzopoulos G: Cancer-specific variation in emergency presentation by sex, age and deprivation across 27 common and rarer cancers. Br J Cancer 2015;112(suppl 1):S129-S136.
19.
Horstmann M, Witthuhn R, Falk M, Stenzl A: Gender-specific differences in bladder cancer: a retrospective analysis. Gend Med 2008;5:385-394.
20.
Puente D, Malats N, Cecchini L, et al: Gender-related differences in clinical and pathological characteristics and therapy of bladder cancer. Eur Urol 2003;43:53-62.
21.
Brookfield KF, Cheung MC, Gomez C, et al: Survival disparities among African American women with invasive bladder cancer in Florida. Cancer 2009;115:4196-4209.
22.
Scosyrev E, Noyes K, Feng C, Messing E: Sex and racial differences in bladder cancer presentation and mortality in the US. Cancer 2009;115:68-74.
23.
Mungan NA, Kiemeney LA, van Dijck JA, van der Poel HG, Witjes JA: Gender differences in stage distribution of bladder cancer. Urology 2000;55:368-371.
24.
Report: Cancer in Germany 2007/2008. Berlin, Robert Koch Institute, 2012. https://www.gbe-bund.de/pdf/KID2012_E.pdf (accessed December 2015).
25.
Fleshner NE, Herr HW, Stewart AK, Murphy GP, Mettlin C, Menck HR: The National cancer data base report on bladder carcinoma. The American college of surgeons commission on cancer and the American cancer society. Cancer 1996;78:1505-1513.
26.
Waldhoer T, Berger I, Haidinger G, et al: Sex differences of ≥ pT1 bladder cancer survival in Austria: a descriptive, long-term, nation-wide analysis based on 27,773 patients. Urol Int 2015;94:383-389.
27.
Soave A, Dahlem R, Hansen J, et al: Gender-specific outcomes of bladder cancer patients: a stage-specific analysis in a contemporary, homogenous radical cystectomy cohort. Eur J Surg Oncol 2015;41:368-377.
28.
National Cancer Intelligence Network: Rare Bladder Cancers. http://www.ncin.org.uk/publications/data_briefings/rare_bladder_cancers (accessed December 2015).
29.
Messer JC, Shariat SF, et al: Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysis. Urology 2014;83:863-867.
30.
Konety BR, Joslyn SA: Factors influencing aggressive therapy for bladder cancer: an analysis of data from the SEER program. J Urol 2003;170:1765-1771.
31.
Chamie K, Saigal CS, Lai J, et al: Compliance with guidelines for patients with bladder cancer: variation in the delivery of care. Cancer 2011;117:5392-5401.
32.
Snyder C, Harlan L, Knopf K, Potosky A, Kaplan R: Patterns of care for the treatment of bladder cancer. J Urol 2003;169:1697-1701.
33.
Noon AP, Albertsen PC, Thomas F, Rosario DJ, Catto JW: Competing mortality in patients diagnosed with bladder cancer: evidence of treatment in the elderly and female patients. Br J Cancer 2013;108:1534-1540.
34.
Schrag D, Mitra N, Xu F, et al: Cystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the Medicare population. Urology 2005;65:1118-1125.
35.
May M, Bastian PJ, Brookman-May S, et al: Gender-specific differences in cancer-specific survival after radical cystectomy for patients with urothelial carcinoma of the urinary bladder in pathologic tumor stage T4a. Urol Oncol 2013;31:1141-1147.
36.
Otto W, May M, Fritsche HM, et al: Analysis of sex differences in cancer-specific survival and perioperative mortality following radical cystectomy: results of a large German multicenter study of nearly 2500 patients with urothelial carcinoma of the bladder. Gend Med 2012;9:481-489.
37.
May M, Stief C, Brookman-May S, et al: Gender-dependent cancer-specific survival following radical cystectomy. World J Urol 2012;30:707-713.
38.
Ahmadi N, Delprado WJ, Brooks AJ, et al: Pathological evaluation and quality of surgery in radical cystectomy in New South Wales, Australia. ANZ J Surg 2015;85:145-149.
39.
Chamie K, Litwin MS, Bassett JC, et al: Recurrence of high-risk bladder cancer: a population-based analysis. Cancer 2013;119:3219-3227.
40.
Thomas F, Noon AP, Rubin N, Goepel JR, Catto JW: Comparative outcomes of primary, recurrent, and progressive high-risk non-muscle-invasive bladder cancer. Eur Urol 2013;63:145-154.
41.
Palou J, Sylvester RJ, Faba OR, et al: Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin. Eur Urol 2012;62:118-125.
42.
Kluth LA, Fajkovic H, Xylinas E, et al: Female gender is associated with higher risk of disease recurrence in patients with primary T1 high-grade urothelial carcinoma of the bladder. World J Urol 2013;31:1029-1036.
43.
Keck B, Ott OJ, Häberle L, et al: Female sex is an independent risk factor for reduced overall survival in bladder cancer patients treated by transurethral resection and radio- or radiochemotherapy. World J Urol 2013;31:1023-1028.
44.
Kluth LA, Rieken M, Xylinas E, et al: Gender-specific differences in clinicopathologic outcomes following radical cystectomy: an international multi-institutional study of more than 8000 patients. Eur Urol 2014;66:913-919.
45.
Tilki D, Svatek RS, Karakiewicz PI, et al: Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients. J Urol 2010;183:87-93.
46.
Lawrentschuk N, Ooi J, Pang A, Naidu KS, Bolton DM: Cystoscopy in women with recurrent urinary tract infection. Int J Urol 2006;13:350-353.
47.
Van Haarst EP, Van Andel G, Heldeweg EA, Schlatmann TJ, Van Der Horst HJ: Evaluation of the diagnostic workup in young women referred for recurrent lower urinary tract infections. Urology 2001;57:1068-1072.
48.
Idriz S, Gao H, Malone-Lee M, et al: Bladder Cancer Is Not Associated with Irritative Lower Urinary Tract Symtoms. Conference Proceedings Paper. San Francisco, 39th Annual Meeting of ICS, 2009.
49.
Wu JM, Williams KS, Hundley AF, Jannelli ML, Visco AG: Microscopic hematuria as a predictive factor for detecting bladder cancer at cystoscopy in women with irritative voiding symptoms. Am J Obstet Gynecol 2006;194:1423-1426.
50.
Burge F, Maliki M, Nkwam N, Wasden A, Parkinson R: Irritative LUTS as a Sign of Cancer: Is Flexible Cystoscopy Indicated? Unmoderated Poster. 34th Congress of the Societe Internationale d'Urologie, 2014.
51.
NICE Guidelines: Suspected Cancer: Recognition and Referral. Bladder Cancer. https://www.nice.org.uk/guidance/ng12/chapter/1-Recommendations-organised-by-site-of-cancer#urological-cancers (accessed July 1, 2015).
52.
Duldulao KE, Diokno AC, Mitchell B: Value of urinary cytology in women presenting with urge incontinence and/or irritative voiding symptoms. J Urol 1997;157:113-116.
53.
Chan ES, Ng CF, Hou SM, Yip SK: Using urine microscopy and cytology for early detection of bladder cancer in male patients with lower urinary tract symptoms. Int Urol Nephrol 2011;43:289-294.
54.
Shariat SF, Karam JA, Lotan Y, Karakiewizc PI: Critical evaluation of urinary markers for bladder cancer detection and monitoring. Rev Urol 2008;10:120-135.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
